Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection
– VOWST is now available by prescription in the U.S. for adult patients following antibiotic treatment for recurrent CDI – – VOWST Voyage™ Support Program to help reduce... | June 5, 2023
Source: marketscreener.com